Market Overview

UPDATE: Cantor Fitzgerald Downgrades Galena Biopharma

Related GALE
Galena Biopharma Collaborates With the National Cancer Institute on a Phase 2 Clinical Trial With NeuVax(TM) (nelipepimut-S) in Ductal Carcinoma in Situ Patients
Galena Biopharma Launches Zuplenz Oral Soluble Film

In a research note released Tuesday, Cantor Fitzgerald downgraded Galena Biopharma (NASDAQ: GALE) from Buy to Sell and set the price target at $3.50.

Cantor analyst Mara Goldstein based the downgrade on, "Concerns of an overhang created by recent news of the use of promotional practices by a contracted investor relations firm and stock sales by insiders." Goldstein continued to stress that these factors may lead to a shareholder lawsuit, noting that an investigation was announced on February 17.

In an explanation of the stocks valuation Goldstein stated, "We have valued Galena shares on a discounted net present value calculation given that near-term earnings are unlikely, but we now think that the shares will be constrained by a valuation of near-term prospects." One such near-term prospect is Galena's recent acquisition of ABSTRAL, which Goldstein says is "off to a good start", but believes it to be unlikely that it will offset the development costs of NeuVax

At last check, Galena was up just over 2 percent at $3.82.

Latest Ratings for GALE

Sep 2015Raymond JamesInitiates Coverage onOutperform
Nov 2014MLV & Co.ReiteratesBuy
Nov 2014Cantor FitzgeraldMaintainsSell

View More Analyst Ratings for GALE
View the Latest Analyst Ratings

Posted-In: Cantor Fitzgerald Marc GoldsteinAnalyst Color Downgrades Price Target Analyst Ratings


Related Articles (GALE)

View Comments and Join the Discussion!

Get Benzinga's Newsletters